EUVIMEDEUVIMED entdecken
Open Access

Molecular Testing Among Patients With Advanced Non–Small Cell Lung Cancer in the Rural US

Dena P Rhinehart, Evelien van Gelderen, Josephine Feliciano, Craig Evan Pollack, Kristen A Marrone, Amanda L Blackford

JAMA Network Open · 05.11.2026 · 9 (11) · e2642270

DOI: 10.1001/jamanetworkopen.2026.42270 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 05.11.2026. Verfasst von Dena P Rhinehart und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Rural Population, Molecular Diagnostic Techniques. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Molecular evaluation is standard of care for patients with advanced non–small cell lung cancer (NSCLC) in the US. Patients in rural areas face disproportionate lung cancer mortality associated with reduced guideline-concordant evaluation and treatment receipt, but molecular testing patterns have not been described in this population.

Objective

To characterize molecular testing patterns in the rural US following initial testing implementation. Design, Setting, and Participants This cohort study used the Surveillance, Epidemiology, and End Results Program linked to Medicare claims data to identify individuals aged 66 years or older diagnosed with advanced NSCLC from January 2014 to December 2019. Data analysis was performed from December 2025 to August 2026. Exposures Sociodemographic variables, histology, and practitioner visits. Main Outcomes and Measures The primary outcome was receipt of molecular testing. The cumulative incidence of testing overall and by patient subgroups defined at baseline were calculated using the total person-time at risk (30 days before diagnosis to death or 6 months after diagnosis) using a competing-risks framework, with death as the competing event.

Results

Among a total of 8259 Medicare beneficiaries residing in rural areas who were diagnosed with advanced NSCLC included in the study (mean [SD] age, 76.1 [6.7] years; 4672 males [56.6%]), 1775 (21.5%) were eligible for Medicaid, 3754 (45.5%) had adenocarcinoma histology, 2044 (24.7%) had squamous histology, and 2461 (29.8%) had other or unspecified histology. In the cohort, 2963 (35.9%) received molecular testing. The cumulative incidence of testing by 180 days after diagnosis was 0.36 (95% CI, 0.35-0.37). Increasing age (hazard ratio [HR], 0.96 [95% CI, 0.93-0.99]), later diagnosis year (HR, 1.05 [95% CI, 1.02-1.07]), dual Medicaid coverage (HR, 0.71 [95% CI, 0.64-0.79]), Part D enrollment (HR, 1.13 [95% CI, 1.04-1.22]), and squamous histology (HR, 0.35 [95% CI, 0.32-0.39]) were independently associated with testing. A greater percentage of patients who received testing had visits with both a proceduralist or a surgeon and an oncologist compared with those without testing (1257 [77.7%] vs 867 [58.9%]; P < .001). Conclusions and Relevance In this cohort study of Medicare beneficiaries with advanced NSCLC residing in the rural US, initial receipt of molecular testing was low. Dual Medicaid coverage, Part D enrollment, and subspecialist visits were independently associated with test receipt, highlighting key areas for future study to promote equitable delivery of guideline-concordant lung cancer care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsRural PopulationMolecular Diagnostic TechniquesHumansMaleFemaleAgedUnited StatesAged, 80 and overSEER ProgramMedicareCohort Studies

Autor:innen und Institutionen

  • Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland.
  • School of Medicine, Johns Hopkins University, Baltimore, Maryland.
  • Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.
  • Johns Hopkins School of Nursing, Johns Hopkins University, Baltimore, Maryland.

Zitieren

APA

Rhinehart, D. P., van Gelderen, E., Feliciano, J., Pollack, C. E., Marrone, K. A., & Blackford, A. L. (2026). Molecular Testing Among Patients With Advanced Non–Small Cell Lung Cancer in the Rural US. JAMA Network Open, 9(11), e2642270. https://doi.org/10.1001/jamanetworkopen.2026.42270

Vancouver

Rhinehart DP, van Gelderen E, Feliciano J, Pollack CE, Marrone KA, Blackford AL. Molecular Testing Among Patients With Advanced Non–Small Cell Lung Cancer in the Rural US. JAMA Network Open. 2026;9(11):e2642270. doi:10.1001/jamanetworkopen.2026.42270

BibTeX
@article{Rhinehart2026,
  author = {Rhinehart, Dena P and van Gelderen, Evelien and Feliciano, Josephine and Pollack, Craig Evan and Marrone, Kristen A and Blackford, Amanda L},
  title = {Molecular Testing Among Patients With Advanced Non–Small Cell Lung Cancer in the Rural US},
  journal = {JAMA Network Open},
  year = {2026},
  volume = {9},
  number = {11},
  pages = {e2642270},
  doi = {10.1001/jamanetworkopen.2026.42270}
}
Kostenlos starten →